[go: up one dir, main page]

SE9301877D0 - IN SITU GEL FOR THERAPEUTIC USE - Google Patents

IN SITU GEL FOR THERAPEUTIC USE

Info

Publication number
SE9301877D0
SE9301877D0 SE9301877A SE9301877A SE9301877D0 SE 9301877 D0 SE9301877 D0 SE 9301877D0 SE 9301877 A SE9301877 A SE 9301877A SE 9301877 A SE9301877 A SE 9301877A SE 9301877 D0 SE9301877 D0 SE 9301877D0
Authority
SE
Sweden
Prior art keywords
therapeutic use
situ gel
liquid
situ
drugs
Prior art date
Application number
SE9301877A
Other languages
Swedish (sv)
Inventor
*Carlfors Johan
*Edsman Katarina
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9301877A priority Critical patent/SE9301877D0/en
Publication of SE9301877D0 publication Critical patent/SE9301877D0/en
Priority to AU69405/94A priority patent/AU6940594A/en
Priority to CA 2164113 priority patent/CA2164113A1/en
Priority to EP94917868A priority patent/EP0706372A1/en
Priority to JP7500555A priority patent/JPH08510731A/en
Priority to PCT/SE1994/000522 priority patent/WO1994027578A1/en

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical drug delivery composition, especially for ophthalmological use, comprising: a liquid hypotonic solution of at least one hydrophilic polymer of the type which undergoes liquid-gel phase transition gelling in situ in contact with a physiological solution, and a pharmaceutically active compound, as well as the use thereof for local administration of drugs.
SE9301877A 1993-06-02 1993-06-02 IN SITU GEL FOR THERAPEUTIC USE SE9301877D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9301877A SE9301877D0 (en) 1993-06-02 1993-06-02 IN SITU GEL FOR THERAPEUTIC USE
AU69405/94A AU6940594A (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use
CA 2164113 CA2164113A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use
EP94917868A EP0706372A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use
JP7500555A JPH08510731A (en) 1993-06-02 1994-06-01 In situ produced gel for therapeutic use
PCT/SE1994/000522 WO1994027578A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9301877A SE9301877D0 (en) 1993-06-02 1993-06-02 IN SITU GEL FOR THERAPEUTIC USE

Publications (1)

Publication Number Publication Date
SE9301877D0 true SE9301877D0 (en) 1993-06-02

Family

ID=20390132

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9301877A SE9301877D0 (en) 1993-06-02 1993-06-02 IN SITU GEL FOR THERAPEUTIC USE

Country Status (6)

Country Link
EP (1) EP0706372A1 (en)
JP (1) JPH08510731A (en)
AU (1) AU6940594A (en)
CA (1) CA2164113A1 (en)
SE (1) SE9301877D0 (en)
WO (1) WO1994027578A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746014B1 (en) * 1996-03-13 1999-01-08 LIQUID-GEL PHASE TRANSITION TYPE OPHTHALMOLOGICAL COMPOSITION
AU2287597A (en) * 1996-03-13 1997-10-01 Laboratoires Merck Sharp & Dohme - Chibret Snc Ophthalmological composition of the type which undergoes liquid-gel phase tr ansition
FR2754712B1 (en) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab OPHTHALMIC COMPOSITIONS
JP2001508411A (en) * 1996-11-29 2001-06-26 モンサント・カンパニー Lubricious free-standing (intact) gel for oral administration of biologically active ingredients
JP2004189731A (en) * 2002-11-26 2004-07-08 Taisho Pharmaceut Co Ltd Nasal drops
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
JP5304108B2 (en) * 2007-08-30 2013-10-02 大正製薬株式会社 Eye drops
DE102010023949A1 (en) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ lecithin microemulsion gel formulation
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
WO2016100086A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Cvs transplantation for treatment of bacterial vaginosis
CN107635545A (en) 2015-01-27 2018-01-26 约翰霍普金斯大学 Hypotonic hydrogel formulations for enhanced delivery of active agents at mucosal surfaces
CN109260146A (en) * 2018-10-12 2019-01-25 广州大光制药有限公司 Ophthalmic solution sodium in situ forming eye type gel eyedrop and preparation method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588189B1 (en) * 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
FR2657018A1 (en) * 1990-01-12 1991-07-19 Merck Sharp & Dohme FLUID OPHTHALMIC COMPOSITION BASED ON LIPID MICROPARTICLES CONTAINING AT LEAST ONE ACTIVE INGREDIENT AND PROCESS FOR PREPARING THE SAME.
CA2040460C (en) * 1990-05-01 1997-06-10 Tacey X. Viegas Drug delivery with thermoreversible gels
DE69212850T2 (en) * 1991-01-15 1997-03-06 Alcon Lab Inc Use of carrageenan in topical ophthalmic compositions

Also Published As

Publication number Publication date
AU6940594A (en) 1994-12-20
CA2164113A1 (en) 1994-12-08
EP0706372A1 (en) 1996-04-17
JPH08510731A (en) 1996-11-12
WO1994027578A1 (en) 1994-12-08

Similar Documents

Publication Publication Date Title
EP0694310A1 (en) Reversible, thermally gelling water-base medicinal composition
IT1261849B (en) MEDICAL DEVICE FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OR VERY LOW DOSAGE DRUGS, IN PARTICULAR HOMEOPATHIC DRUGS.
DE3681582D1 (en) PHARMACEUTICAL PREPARATION WITH DELIVERY CHARACTERISTICS.
GB0015617D0 (en) Improved preparations for dermal delivery of active substances
CO5130022A1 (en) DRUG CONTROLLED DELIVERY SYSTEM ORALALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL
EA200101026A1 (en) PRELIMINARY GELATINIZED STARCH IN COMPOSITION WITH CONTROLLED DELIVERY
CA2388610A1 (en) Oral transmucosal drug dosage using solid solution
WO2001085137A3 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GT199900151A (en) DRUG CONTROLLED DELIVERY SYSTEM ORALALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL.
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
SE9703191D0 (en) Medication for improvement of duration of muscle function or treatment of muscle disorders or diseases
SE9301877D0 (en) IN SITU GEL FOR THERAPEUTIC USE
WO1994010987A1 (en) Combined analgesic delivery methods for pain management
ATE202926T1 (en) PHARMACEUTICAL EFFECTIVE PREPARATIONS CONTAINING BIODEGRADABLE MICROCAPSULES FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS
ATE292453T1 (en) ANTIVIRAL DRUG
KR20230050475A (en) Topical polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
KR970705402A (en) DISEASE AND CONDITIONS ASSOCIATED WITH MACROPHAGE IN INFILTRATION IN PARTICULAR STROKE AND MYOCARDIAL INFARCTION.
WO2003101378A3 (en) Pharmaceutical formulation in a drug delivery system and process for preparing the same
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
WO2023150579A3 (en) Pharmaceutical formulations containing nalbuphine
AR012996A1 (en) USE OF AN INSULIN SENSITIZER FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH SENSITIZER.
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
US7658947B2 (en) Thermo-gelling composition
Sam et al. Hydrogel Matrix Diffusion Technology: Development of Controlled Release Formulation Aiming for Enhanced Adherence.